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Abstract
In a structure-activity relationship (SAR) study, 3-methoxy-1,4-phenanthrenequinones, calanquinone A (6a), denbinobin
(6b), 5-OAc-calanquinone A (7a) and 5-OAc-denbinobin (7b), have significantly promising cytotoxicity against various
human cancer cell lines (IC50 0.08–1.66 mg/mL). Moreover, we also established a superior pharmacophore model for
cytotoxicity (r=0.931) containing three hydrogen bond acceptors (HBA1, HBA2 and HBA3) and one hydrophobic feature
(HYD) against MCF-7 breast cancer cell line. The pharmacophore model indicates that HBA3 is an essential feature for the
oxygen atom of 5-OH in 6a–b and for the carbonyl group of 5-OCOCH3 in 7a–b, important for their cytotoxic properties. The
SAR for moderately active 5a–b (5-OCH3), and highly active 6a–b and 7a–b, are also elaborated in a spatial aspect model.
Further rational design and synthesis of new cytotoxic phenanthrene analogs can be implemented via this model.
Additionally, employing a ChemGPS-NP based model for cytotoxicity mode of action (MOA) provides support for
a preliminary classification of compounds 6a–b as topoisomerase II inhibitors.
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Introduction
Natural phenanthrenes are probably generated from photo-
chemical cyclization of stilbenes [1]. More than 270 phenan-
threnes have been isolated from natural products, especially the
family Orchidaceae, and some of them possess various biological
activities, including cytotoxicity, antiplatelet aggregation, anti-
inflammatory, antimicrobial, spasmolytic, anti-allergic activities
and phytotoxicity [1]. In our previous study, calanquinone A [5-
hydroxy-3,6,7-trimethoxy-1,4-phenanthrenequinone (5-hydroxy-
3,6,7-trimethoxy-1,4-PQ)] (Figure 1), a new PQ isolated from
Calanthe arisanensis in 2008, showed significant cytotoxic activity
against human lung (A549), prostate (PC-3 and DU145), colon
(HCT-8), breast (MCF-7), nasopharyngeal (KB), and vincristine-
resistant nasopharyngeal (KBVIN) cancer cell lines with EC50
values of 0.03–0.45 mg/mL [2,3]. Calanquinone A is related in
structure to other naturally occurring cytotoxic PQs, including
denbinobin (Figure 1) (5-hydroxy-3,7-dimethoxy-1,4-PQ), sphe-
none A (3,6,7-trimethoxy-1,4-PQ), densiflorol B (7-hydroxy-2-
methoxy-1,4-PQ), and annoquinone A (3-methoxy-1,4-PQ) [1].
Denbinobin, first isolated from Dendrobium nobile in 1981, is the
only 1,4-PQ that has been studied in terms of the cytotoxic
mechanisms of human colon (HCT-116 and COLO 205), lung
adenocarcinoma (A549), myelogenous leukemia (K562), and
pancreatic adenocarcinoma (BxPC-3) cancer cell lines [4–11].
The data implied that denbinobin could be a potential antican-
cer lead compound.
In our preliminary results of cytotoxic structure-activity re-
lationship (SAR) studies, calanquinone A (6a) displayed an up to
7-fold greater cytotoxic activity than denbinobin (6b), which is
known as a potent cytotoxic agent [4–11], toward human liver
(HepG2 and Hep3B), oral (Ca9-22), lung (A549) and breast
(MEA-MB-231 and MCF7) cancer cell lines. Up to now, the SAR
of PQs and phenanthrenes has only rarely been reported and is
worthy of further study. In this research, calanquinone A (6a),
denbinobin (6b) and their derivatives were synthesized [3,12,13]
and evaluated for cytotoxic activity. In addition, employing
a ChemGPS-NP based model provides the prediction for
cytotoxicity mode of action (MOA) of calanquinone A (6a) and
denbinobin (6b).
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Chemistry
Eleven natural phenanthrene analogs (CA-1-11) (Figure 2) were
isolated from C. arisanensis, and calanquinone A (CA-1) exhibited
the highest potency against human cancer cell lines [2,3].
According to the previous results [3], calanquinone A (CA-1)
was selected as a lead compound and its derivatives were then
synthesized for this study.
We modified the synthetic procedure of Dr. Kraus and his co-
workers [12,13] to synthesize all phenanthrene derivatives. As
shown in Figure 3, 2-aldehyde-1,4-quinone was prepared by DDQ
oxidation of commercially available 2,5-dihydroxybenzaldehyde.
The quinone was coupled with 3,4,5-trimethoxytoluene and 3,5-
dimethoxytoluene in the presence of 1 equivalent of trifluoroacetic
acid to produce 1a and 1b, respectively. Compounds 1a and 1b
were methylated with Me2SO4 in the presence of K2CO3 (acetone,
60uC, 5 h) to give the desired 2a and 2b. Cyclization of 2a and 2b
with P4-tBu (benzene, 110 or 140uC, 19–29 h) gave phenanthrenes
3a and 3b, which were oxidized with AgO (6 N HNO3, acetone,
50uC, 2–3 min) to phenanthrenequinone 4a, 4b and 4c. Addition
of methanol to 4a, 4b and 4c catalyzed by ferric sulfate [14] gave
5a–f,respectively (Figure 4).Compounds 7a and 7b were obtained
by treatment of 5a and 5b with TMSI (CH2Cl2,R To r6 0 uC,
monitored by TLC) to give calanquinone A (6a; CA-1) and
denbinobin (6b), followed by treatment with Ac2O (pyridine, RT,
overnight) to selectively remove the methyl group and incorporate
an acetyl group at C-5, respectively (Figure 5). It is a characteristic
feature of the angular arrangement of 1,4-phenanthrenequinones
which led to remarkable selectivity in the cleavage of sterically
hindered methyl ether at C-5 even in preference of that at C-3.
However, applying TMSI to remove the methyl groups in
phenanthrenes 3a and 3b was unsuccessful. Finally, cleavage of
the methyl ether groups in 3a and 3b with AlCl3 generated
compounds 8a & 9a and 8b & 9b, respectively (Figure 6). The
excess AlCl3 regioselectively cleaved the methyl ethers only at C-4
and C-5 or C-6 in order to release the steric strain.
Cytotoxicity
The cytotoxic assay of 11 naturally occurring and 19
synthesized phenanthrenes was carried out on a diverse set of
human liver (HepG2 and Hep3B), oral (Ca9-22), lung (A549) and
breast (MEA-MB-231 and MCF7) cancer cell lines, and a human
fetal lung fibroblast (MRC-5) cell line (Tables 1 and 2).
Doxorubicin was used as a positive control and an IC50.4 mg/
mL was considered inactive.
Among the 11 naturally occurring compounds [2], calanqui-
none A (CA-1) (5-OH, 6-OCH3) and calanquinone B (CA-2) (5-
OCH3, 6-OH) simply have reversed placements of the OH and
one OCH3 group, but CA-2 was much less potent than CA-1
(Figure 2 and Table 1). The SAR results of CA-1 and CA-2 could
possibly be explained by intramolecular hydrogen bonding
between C=O (C-4) and OH (C-5) groups in 3-methoxy-1,4-
PQs that may be a necessary moiety for cytotoxicity. To set up
SAR correlations and identify active phenanthrene analogs,
calanquinone A (CA-1) was selected as a lead compound for
further studies.
Accordingly, 19 analogues including calanquinone A (6a; CA-
1) were synthesized and tested in cytotoxicity assays. As shown in
Table 2, calanquinone A (6a) and denbinobin (6b) exhibited
significant potency against all cancer cell lines (IC50 0.08–
1.06 mg/mL). PQs 7a and 7b also showed very high potency
against five cancer cell lines (IC50 0.16–1.66 mg/mL), not
including HepG2. Conversely and interestingly, PQs 5d and
5e were active only against the HepG2 cancer cell line with IC50
values of 1.49 and 1.24 mg/mL, respectively. PQs 4a, 4b, 4c
and phenanthrene 8a displayed selective activity toward the
Ca9-22 cancer cell line with IC50 values of 2.17, 3.45, 1.90 and
3.91 mg/mL, respectively. The SAR study of cytotoxicity
suggested that the skeleton of 1,4-PQ is preferable to that of
phenanthrene. To evaluate a potential SAR of the intramolecular
hydrogen bond between C-4 and C-5, 3-methoxy-1,4-PQs 5a–b,
6a–b and 7a–b were designed. Compounds 6a and 6b, with
OH at C-5 and C=O at C-4, can form an intramolecular
hydrogen bond. However, the hydrogen donors of 5a–b and
7a–b have been replaced with OCH3 and OAc groups,
respectively. Among the six 3-methoxy-1,4-PQs, 6a and 6b
exhibited the most significant potency, especially 6a (IC50 0.08–
0.89 mg/mL). Compounds 5a and 5b showed marginal activities
against all human cancer cell lines. Surprisingly, the new 7a and
7b, with OAc at C-5 and C=O at C-4, were active toward five
human cancer cell lines (IC50 0.16–1.66 mg/mL), but not
HepG2. These data also represent the first time we have found
this phenomenon in a cytotoxic assay of PQ derivatives. To
expand upon the SAR study, all natural and synthesized
compounds were used for the 3D pharmacophore model
building.
3D Pharmacophore Modeling
To further identify the critical structural features of the
phenanthrene analogs, 29 compounds (Figure 2) were used for
pharmacophore modeling with Catalyst HypoGen. In this spatial
aspect model, the phenanthrene structures and their cytotoxicity
toward MCF-7 cancer cell line showed some interesting in-
formation.
The best pharmacophore model was established as a result of
thirty runs with various parameters and characterized by a best
correlation coefficient (0.931), the lowest total cost value (109.366),
the highest cost difference (42.417), and the lowest RMS (0.790)
(for details see Tables S1, S2 and Figure S1; Text S1). As shown in
Figure 7, four essential features, three hydrogen bond acceptors
(HBA1, HBA2 and HBA3) and one hydrophobic feature (HYD)
were defined. All mutual distances of the four features can be
measured. The distances between HBA1 and HBA2 or HBA3
were found to be 5.13 and 7.40 A ˚, respectively. The distances
Figure 1. Structures of calanquinone A and denbinobin.
doi:10.1371/journal.pone.0037897.g001
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doi:10.1371/journal.pone.0037897.g002
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5.92 A ˚, respectively. The distances between HYD and HBA1 or
HBA3 were found to be 3.83 and 4.78 A ˚, respectively. The
distance between HBA2 and HBA3 is especially critical for the
MCF-7 cytotoxic effect in this model.
The mappings of the best model with all compounds show fit
values ranging from 6.18 to 8.57 (Table S3; Text S1).
Calanquinone A (6a) mapped to the best hypothesis model with
the fit value of 8.57 reveals significant features in Figure 8A.
Obviously, the HBA1 links to the carbonyl group of quinone ring
at C-1, HBA2 links to the oxygen atom of the methoxyl group at
C-3, HBA3 links to the oxygen atom of the hydroxyl group at C-5,
and HYD aligns to the aromatic ring (B-ring). Compound 6b has
a similar alignment as 6a, with a high fit value of 7.95 (Figure 8B
and Table S3). As shown in Figures 8C and 8D, 7a and 7b,
which are highly toxic to MCF-7 cells, also match against all
features of the best hypothesis in which 7a was originally designed
to remove the intramolecular hydrogen bond and was previously
speculated to be less cytotoxic. The main difference in structure
between 7a–b and 6a–b is the carbonyl group of the acetoxyl
substituent at C-5. Consequently, the conserved distance between
HBA2 and HBA3 explains why 7a and 7b, with OCOCH3 at C-5
and C=O at C-4 but without the same intramolecular hydrogen
bonds as 6a and 6b, can still possess significant cytotoxicity, in
contrast to our previous speculation. For less MCF-7 cytotoxic
compounds, mismatching one hydrogen bond in the triad and thus
disrupting the structures of 5a and 5b results in moderate
inhibition, one order higher in mg/mL. The oxygen atom of the
methoxyl group at C-6, the carbonyl group at the C-4 position,
and the aromatic atom at C-9 of 5a fit into the HBA2, HBA3 and
Figure 3. Synthetic procedure of phenanthrene derivatives. Reagents and conditions: (i) DDQ, benzene, RT. (ii) TFA, ether, RT. (iii) Me2SO4,
K2CO3, acetone, reflux. (iv) P4-tBu, benzene, 140uC. (v) AgO, 6 N HNO3, acetone, 60uC.
doi:10.1371/journal.pone.0037897.g003
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(Figure 8E). Also, the carbonyl group at C-1, the oxygen atom
of the methoxyl group at C-3, and the aromatic atom at C-9 of 5b
match against HBA1, HBA2 and HYD features, but are not linked
to HBA3 (Figure 8F).
Thus, HBA1, 2 and 3 complete the triad of the hydrogen
acceptor feature and clearly explain the MCF-7 cytotoxic variation
of 5a–b, 6a–b and 7a–b. In addition, the hydrophobic feature
HYD indicates a pharmacophore anchor for a three-ring core as
in phenanthrene and PQ derivatives in the series. The hydropho-
bic feature links to all compounds and the HBA feature always
Figure 4. Synthesis of methoxy-phenanthrenequinones. Reagents and conditions: (i) MeOH, Fe2(SO4)3, PTSA, 70uC.
doi:10.1371/journal.pone.0037897.g004
Figure 5. Selective demethylation and acetylation of phenanthrenequinones. Reagents and conditions: (i) TMSI, CH2Cl2,R To r6 0 uC. (ii)
Ac2O, pyridine, RT.
doi:10.1371/journal.pone.0037897.g005
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PQs. As a whole, a pharmacophore and explicit SAR were
established herein.
ChemGPS-NP Analysis of Calanquinone A (6a) and
Denbinobin (6b)
ChemGPS-NP (chemical global positioning system for natural
products) is a computational model based on principal component
analysis of physical-chemical properties. Such properties can be
estimated directly from structure data, and by performing score
prediction in the ChemGPS-NP model, this provides a versatile
tool for charting and navigating the biologically relevant chemical
space [15]. In a previous study ChemGPS-NP has successfully
been used to chart a set of known anticancer agents with different
cytotoxic mechanisms. The resulting map has been used as a tool
to predict the anticancer Mode of Action (MOA) for new and
previously unstudied lead compound [16]. As shown in Figure 9,
the two most potent cytotoxic compounds, calanquinone A (6a)
Figure 6. Demethylation of phenanthrenes. Reagents and conditions: (i) AlCl3, benzene, 70uC.
doi:10.1371/journal.pone.0037897.g006
Table 1. Cytotoxicity data of natural phenanthrenes isolated from C. arisanensis.
IC50 (mg/mL)/Cell line
Compd HepG2 Hep3B Ca9-22 A549 MCF-7 MDA-MB-231 MRC-5
CA-1 0.2160.01 0.2260.00 0.1760.01 0.1160.00 0.0960.00 0.6460.06 0.6560.00
CA-2 14.4760.43 11.9460.55 14.6460.11 18.5060.29 11.9060.08 .20 .20
CA-3 19.7660.16 6.0260.12 12.5560.76 .20 13.2560.00 11.9060.02 .20
CA-4 .20 11.0560.73 15.1260.14 .20 14.3060.18 19.8360.45 .20
CA-5 17.8060.40 9.8760.09 12.1760.03 .20 12.7060.07 11.6660.13 .20
CA-6 .20 11.5060.76 14.5660.31 .20 .20 .20 .20
CA-7 .20 .20 .20 .20 14.6260.34 .20 .20
CA-8 .20 .20 .20 .20 .20 .20 .20
CA-9 .20 12.8960.32 12.9960.42 18.1160.26 10.2560.27 19.4860.58 .20
CA-10 7.5260.00 7.2460.18 6.1160.51 7.4660.32 6.7760.12 7.5660.03 16.3960.36
CA-11 7.1760.35 6.2860.26 5.8660.06 7.4060.01 4.8460.89 7.4260.03 13.1760.33
Doxo
a 0.2260.04 0.4960.00 0.1660.02 0.8160.04 0.6760.03 0.7460.01 1.9460.02
aDoxorubicin (Doxo) was used as the positive control.
doi:10.1371/journal.pone.0037897.t001
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their resulting position on the chemical space map, it can be
concluded that these phenanthrene derivatives do not unambig-
uously belong to any of the well defined groups representing
alkylating agents, antimetabolites, proteasome inhibitions, tyrosine
kinase inhibitors, topoisomerase I, and tubulin inhibitors except
topoisomerase II inhibitors. The preliminary result of this
ChemGPS-NP analysis indicates that calanquinone A (6a) and
denbinobin (6b) might be members of a topoisomerase II
inhibitor, which however, still remains to be further elucidated.
Topoisomerase II Assay
From the ChemGPS-NP analysis, it seems that the MOA for
3-methoxy-1,4-PQs might processes cytotoxicity as a topoisome-
rase II inhibitor. In the previous study [17], 1,4-benzoquinone
has been found to poison human topoisomerase IIa. According
to these results, we chose the most potential calanquinone A (6a)
and its moderate compound 5a to test the DNA cleavage assay,
in which known etoposide (VP-16) was used as the positive
control. As shown in Figure 10, compound 6a showed the
inhibition on Topo IIa in the result of the appearance of
supercoided DNA instead of the relaxed one at the concentration
of 100 mmol/L. Additionally, compound 5a also had the similar
effect at higher concentration (200 mmol/L). Moreover, both
compounds induced the formation of linear DNA, suggesting
that they could possibly trap Topo IIa into DNA cleavage
complex. Our data proved PQs inhibit hTopoII in vitro with
inducing DNA strand breaks and protein covalently bound to
DNA, ultimately leading to cell cycle arrest and death.
Table 2. Cytotoxicity data of synthesized phenanthrenes.
IC50 (mg/mL)/Cell line
Compd HepG2 Hep3B Ca9-22 A549 MCF-7 MDA-MB-231 MRC-5
3a .20 15.5560.08 .20 .20 .20 .20 .20
3b .20 .20 18.4460.11 .20 .20 .20 .20
4a 15.6860.01 7.3360.03 2.1760.01 15.9460.01 13.1960.38 4.6060.06 11.9360.12
4b 18.6460.14 12.1060.33 3.4560.03 .20 15.6360.01 7.0960.01 .20
4c 6.8760.10 4.3760.00 1.9060.01 12.6560.48 4.7160.26 4.0960.12 5.3760.25
5a 4.6560.07 4.6760.81 5.9960.24 11.0460.44 14.2960.50 .20 .20
5b 12.9960.21 15.9560.21 15.2560.05 15.7160.17 14.4060.28 18.9860.55 .20
5c .20 13.7860.38 9.0760.09 11.9962.18 11.1060.02 19.1160.43 .20
5d 1.4960.01 6.6660.13 4.3660.03 9.3060.48 13.7860.06 14.7660.25 .20
5e 1.2460.08 7.3860.02 6.2160.12 7.4960.07 9.4060.00 6.7460.05 8.1160.25
5f 19.6460.74 7.8860.19 4.5760.03 .20 14.7760.21 4.7460.02 .20
6a 0.0860.00 0.1960.01 0.5960.01 0.1460.02 0.2060.00 0.8960.01 0.6060.05
6b 0.2360.01 0.3460.00 0.6860.00 0.9960.02 0.2660.00 1.0660.03 2.1460.08
7a 11.3060.14 0.3660.14 0.8460.05 0.6060.01 0.1660.00 1.1360.05 1.1460.01
7b 13.2360.25 0.6060.11 1.5560.20 1.6660.01 0.5360.03 1.6160.04 2.6460.06
8a 19.3860.56 5.7760.63 3.9160.07 .20 17.0160.42 15.6361.52 .20
9a .20 .20 .20 .20 .20 .20 .20
8b 10.0860.66 6.9360.19 12.0760.37 19.5860.22 19.3160.08 .20 .20
9b .20 .20 .20 .20 .20 .20 .20
Doxo
a 0.2260.02 0.4260.01 0.1460.04 0.6360.15 0.3560.09 1.1260.05 1.9460.02
aDoxorubicin (Doxo) was used as the positive control.
doi:10.1371/journal.pone.0037897.t002
Figure 7. The mutual distances of the hydrogen bond triad and
the distances between hydrogen bonds and hydrophobic
group in the best HypoGen pharmacophore model. The
pharmacophore features are colored with green, as are the hydrogen-
bond acceptors (HBA1, HBA2 and HBA3). The hydrophobic aromatic
feature (HYD) is denoted in cyan. Distances between features are in
A ˚ngstro ¨m units.
doi:10.1371/journal.pone.0037897.g007
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e37897Figure 8. The best HypoGen pharmacophore model mapping onto calanquinone A (6a) and its derivatives. The light and dark green
represent active and inactive features, respectively. The models mapped with the compounds 6a (A), 6b (B), 7a (C), 7b (D), 5a (E) and 5b (F) are
shown here. Pharmacophore features are colored as in Figure 7.
doi:10.1371/journal.pone.0037897.g008
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In summary, a series of phenanthrene derivatives, including the
new derivatives (3a, 4c, 5c–f, 7a, 8a–b and 9a–b), were
synthesized in this investigation. On the basis of our SAR studies,
3-methoxy-1,4-PQs 6a (calanquinone A), 6b (denbinobin), 7a (5-
OAc-calanquinone A) and 7b (5-OAc-denbinobin) were identified
as highly potent cytotoxic agents.
A best ligand-based pharmacophore model against the MCF-7
cancer cell line was successfully established. It explains the SAR of
3-methoxy-1,4-PQs 5a–b (5-OCH3), 6a–b (5-OH) and 7a–b (5-
OCOCH3) in a spatial aspect model. Highly active 6a, 6b, 7a and
7b possess three hydrogen bond acceptors forming a hydrogen
bond triad combined with one hydrophobic group as a pharma-
cophore that can interact with a potential target. The revealed
pharmacophore model provides a bona fide basis for further
design and synthesis of promising phenanthrene structures in vitro
to study their anti-breast cancer properties. On the basis of
ChemGPS-NP prediction and TopoII assay assessment, 1,4-PQs
were suggested as the topoisomerase II inhibitors. This is the first
time to apply ChemGPS-NP to previously untested cytotoxic
compounds for MOA prediction. In the future, ChemGPS-NP
could be used to effectively find the most possible MOA in the new
drug discovery, as suggested by Rose ´n and co-workers [16].
Overall, our data demonstrate that PQs could be promising lead
compounds for the further development of anti-cancer.
Materials and Methods
General
Melting points were determined on a YanacoH digital micro
melting point apparatus model MP-500D without correction.
NMR spectra were recorded on Varian Unity-plus 400 MHz FT-
NMR and Varian Mercury-plus 400 MHz FT-NMR instruments.
Chemical shift (d) values are in ppm (parts per million) with CDCl3
as the internal standard, and coupling constants (J) are in Hz.
Figure 9. ChemGPS-NP analysis of calanquinone A (6a) and denbinobin (6b). Score plot of the three dimensions (principal components 2–
4) consisting of PC2 (yellow; aromaticity etc.), PC3 (green; lipophilicity etc.) and PC4 (orange; flexibility/rigidity), from analysis of most potent
compounds 6a and 6b as medium seagreen cubes in the ChemGPS-NP model addressed by Rose ´n et al. in 2009 for prediction of MOA. A reference
set of known anticancer agents includes alkylating agents (red), anti-metabolites (lime), proteasome inhibitions (cyan), tyrosine kinase inhibitors
(orange), topoisomerase I (blue), topoisomerase II (magenta), and tubulin inhibitors (black).
doi:10.1371/journal.pone.0037897.g009
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a Bruker Daltonics APEX II 30e mass spectrometer. TLC was
performed on Kieselgel 60, F 254 (0.25 nm, Merck), and spots
were viewed under ultraviolet light at 254 and 356 nm. For
column chromatography, silica gel (Kieselgel 60, 70–230, and
230–400 mesh, Merck) and a BiotageH SP system apparatus were
used.
Cytotoxicity ASSAY
Compounds were tested against human liver (HepG2 and
Hep3B), oral (Ca9-22), lung (A549), breast (MEA-MB-231 and
MCF7) cancer cell lines, and the human fetal lung fibroblast
(MRC-5) cell line using an established colorimetric MTT assay
protocol [18]. The absorbance was measured at 550 nm using
a microplate reader. The IC50 is the concentration of agent that
reduced cell growth by 50% under the experimental conditions.
3D Pharmacophore Model
The pharmacophore modeling with Catalyst HypoGen was
performed via Discovery Studio 2.1 (Accelrys, San Diego, CA,
USA) [19]. Twenty-nine phenanthrene derivatives were collected
from the natural plant, C. arisanensis, and from chemical synthesis
(Figure 2). Cytotoxicity against MCF-7 cells was determined by the
MTT assay and the concentration (mg/mL) of test compound
which inhibited 50% of the cancer cells (IC50) was used in the
generation of the pharmacophore model. An IC50 value of
.20 mg/mL was defined as 20 mg/mL. All experimental IC50
values spanned about 2–3 orders of magnitude from 0.09 to
20 mg/mL. The 2D/3D structures of compounds were generated
using ChemBioOffice 2008 (Cambridge Scientic Computing,
Cambridge, Massachusetts, USA) and then optimized in a Dreid-
ing force field. The conformational ensemble of each compound
was generated using the best conformational analysis method
based on a CHARMM force field with a 20 kcal/mol energy
threshold above the global minimum. A maximum limit of 255
conformations was used to cover maximum conformational space.
The best 3D arrangements of chemical functionalities should
explain the activity variations among the 29 compounds. Thirty
runs with different parameters were performed for the best
pharmacophore hypothesis. Four chemical features, including
hydrogen-bond acceptor (HBA), hydrogen-bond donor (HBD),
hydrophobic (HYD), and aromatic ring (AR) features, were also
tested during the building of pharmacophore hypotheses (Table
S1; Text S1). The best hypotheses were selected via a correlation
and a cost analysis in Catalyst HypoGen.
Three costs including the total cost (the sum of weight, error and
configuration cost), the null cost and the fixed cost will be
evaluated. A total cost that is similar to the fixed cost and far from
the null cost indicates statistically significant pharmacophore
hypotheses. A difference between the total cost and null cost
ranging from 40 to 60 indicates a true correlation of the
pharmacophore hypothesis with 75–90% high probability. The
true correlation represents ,50% probability when it is less than
40. Generally, the configuration cost should be smaller than 17 in
a standard HypoGen model. According to the total cost (109.366),
fixed cost (99.558), null cost (151.783), RMS value (0.790), and
correlation coefficient (0.931) (Table S2), the best pharmacophore
hypothesis, run 22, containing three hydrogen-bond acceptors
(HBA1, HBA2, HBA3) and one hydrophobic feature (HYD) was
selected (Figure 7).
ChemGPS-NP
The PCA-based model ChemGPS-NP (http://chemgps.bmc.
uu.se) is a tool for navigation in biologically relevant chemical
space. It has eight principal components (PC; dimensions), derived
from 35 molecular descriptors describing physical-chemical
properties such as size, shape, polarizability, lipophilicity, polarity,
flexibility, rigidity, and hydrogen bond capacity for a reference set
of compounds. The ChemGPS-NP descriptors were calculated for
compounds 6a and 6b on the basis of their structure information
as simplified molecular input line entry specification (SMILES)
using the software DRAGON Professional. Compounds 6a and
Figure 10. Topoisomerase II DNA cleavage assay. An in vitro assay was used to assess the effect of compounds 6a and 5a on the DNA
cleavage activity of human TopoII. Etoposide was the positive control. Control lane: TopoIIa + plasmid DNA. DMSO lane: TopoIIa + plasmid DNA +
DMSO.
doi:10.1371/journal.pone.0037897.g010
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terms of PCA score together with a reference set of known
anticancer agents with previously studied Mode of Action (MOA)
(Anticancer Agent Mechanism Database; http://dtp.nci.nih.gov/
docs/cancer/searches/standard_mechanism.html). Principal com-
ponent and PCA score prediction were calculated employing the
software SIMCA-P+, with the training set ChemGPS-NP. Prior to
PCA determination, all data were centered and scaled to unit
variance [16].
Topoisomeras II Assay
Topoisomerase II assay was performed by using a Topo II Drug
Screening Kit (TopoGEN, Inc.). In brief, 0.1 mg of pHOT
plasmid DNA was incubated with 2 units of topoisomerase IIa in
20 mL assay buffer at 37uC for 40 min in the presence of tested
compounds (6a, 5a) and control drug, etoposide, respectively.
2 mL of 10% SDS and 2.5 mL of 10 mg/mL proteinase K were
added into the reaction sample and then incubated for 30 min at
37uC to digest topoisomerase IIa. The samples were mixed with
2 mL of loading buffer and cleaned up by adding an equal volume
of phenol:chloroform:isoamyl alcohol (25:24:1) according to the
description. The sample was mixed by vortex and centrifuge for
10 sec. An aliquot (10 mL) of the upper aqueous part was analyzed
by electrophoresis with 2% agarose gel containing 0.5 mg/mL of
ethidium bromide [20].
3,6-Dihydroxy-29,39,49-trimethoxy-69-methyl-biphenyl-2-
carbaldehyde (1a). 2,5-dihydroxybenzaldehyde (3.01 g,
21.79 mmol) and DDQ (9.18 g, 40.42 mmol) were dissolved in
dry benzene. The mixture was stirred at RT overnight, and the
benzene was then evaporated. The crude product reacted with
equimolar amounts of 3,4,5-trimethoxytoluene and trifluoroacetic
acid in Et2O at RT for 24 h or for an extended reaction time to
obtain the best yield. The crude product was poured onto ice
water and extracted three times with EtOAc. The EtOAc layer
was washed once with brine and dried with Na2SO4. The product
was chromatographed on silica gel and eluted with CH2Cl2 to give
compound 1a (2.14 g, 31.16%).
1H NMR (CDCl3): d 2.01 (s,
3 H), 3.65 (s, 3 H), 3.87 (s, 3 H), 3.91 (s, 3 H), 4.65 (s, OH), 6.68
(s, 1 H), 6.95 (d, 1 H, J=8.8 Hz), 7.23 (d, 1 H, J=8.8 Hz), 9.45
(s, 1 H), 11.38 (s, OH);
13C NMR (CDCl3): d 19.9, 56.0, 61.0,
61.1, 109.7, 116.2, 117.8, 118.2, 125.2, 125.5, 133.9, 140.5, 145.6,
152.2, 154.4, 156.9, 196.7.
3,6-Dihydroxy-29,49-dimethoxy-69-methyl-biphenyl-2-
carbaldehyde (1b). 2,5-dihydroxybenzaldehyde (771.46 mg,
5.59 mmol), DDQ (2.54 g, 11.17 mmol), 3,5-dimethoxytoluene
(850 mg, 5.59 mmol), and trifluoroacetic acid were used with the
method described for 1a to yield 1b (842.40 mg, 52.69%).
1H
NMR (CDCl3): d 1.91 (s, 3 H), 3.62 (s, 3 H), 3.72 (s, 3 H), 3.85 (s,
3 H), 3.88 (s, 3 H), 3.91 (s, 3 H), 6.58 (s, 1 H), 6.98 (d, 1 H,
J=8.8 Hz), 7.15 (d, 1 H, J=8.8 Hz), 9.98 (s, 1 H);
13C NMR
(CDCl3): d 19.9, 55.8, 56.1, 56.4, 60.5, 60.9, 108.6, 111.4, 117.0,
120.7, 124.5, 130.4, 132.1, 139.8, 151.0, 151.0, 152.8, 154.6,
191.6.
3,6,29,39,49-Pentamethoxy-69-methyl-biphenyl-2-
carbaldehyde (2a). The hydroquinone 1a (2.15 g, 6.76 mmol)
and K2CO3 (10.25 g, 74.16 mmol) were dissolved in acetone and
then dimethyl sulfate (2.13 g, 16.89 mmol) was added. The
mixture was stirred at reflux for 5 h, and the K2CO3 was then
removed by filtration through Celite. The crude product was
chromatographed on silica gel and eluted with EtOAc/n-hexane
(1:2) to yield 2a (1.88 g, 80.57%).
1H NMR (CDCl3): d 2.03 (s,
3 H), 3.70 (s, 3 H), 3.86 (s, 3 H), 4.58 (s, OH), 6.44 (d, 1 H,
J=2.4 Hz), 6.52 (d, 1 H, J=2.4 Hz), 6.92 (d, 1 H, J=8.8 Hz),
7.21 (d, 1 H, J=8.8 Hz), 9.39 (s, 1 H), 11.35 (s, OH);
13C NMR
(CDCl3): d 20.2, 55.4, 55.7, 96.5, 107.2, 110.5, 117.9, 125.2,
125.8, 140.8, 145.6, 156.8, 158.0, 159.0, 161.6, 197.0.
3,6,29,49-Tetramethoxy-69-methyl-biphenyl-2-
carbaldehyde (2b). Compound 1b (8.57 mg, 29.76 mmol),
K2CO3 (41 g, 296.65 mmol), and dimethyl sulfate (11.20 g,
88.80 mmol) were used with the method described for 2a to yield
2b (6.23 g, 66.28%).
1H NMR (CDCl3): d 1.96 (s, 3 H), 3.65 (s,
3 H), 3.69 (s, 3 H), 3.83 (s, 3 H), 3.91 (s, 3 H), 6.37 (d, 1 H,
J=2.4 Hz), 6.44 (d, 1 H, J=2.4 Hz), 6.96 (d, 1 H, J=8.8 Hz),
7.14 (d, 1 H, J=8.8 Hz), 9.85 (s, 1 H);
13C NMR (CDCl3): d 20.2,
55.2, 55.7, 56.1, 56.7, 96.0, 106.4, 111.3, 115.3, 117.3, 124.7,
131.0, 138.9, 151.2, 154.3, 157.8, 160.2, 192.0.
1,4,5,6,7-Pentamethoxy-phenanthrene (3a). Compound
2a (1.18 g, 3.41 mmol) and P4-tBu (1 M, 5.50 mL, 5.45 mmol)
were placed under N2 in benzene and heated to 140uC for 29 h.
The solvent was evaporated and the crude product was
chromatographed on silica gel eluting with EtOAc/n-hexane
(1:2) to yield 3a (1.06 g, 95.04%). Pale yellowish gum;
1H NMR
(CDCl3): d 3.71 (s, 3 H), 3.94 (s, 3 H), 3.99 (s, 3 H), 4.00 (s, 3 H),
4.01 (s, 3 H), 6.91 (d, 1 H, J=8.8 Hz), 6.98 (d, 1 H, J=8.8 Hz),
7.00 (s, 1 H), 7.52 (d, 1 H, J=8.8 Hz), 8.01 (d, 1 H, J=8.8 Hz);
13C NMR (CDCl3): d 56.0, 56.2, 56.5, 60.9, 61.3, 103.09, 105.8,
107.9, 116.8, 119.7, 120.6, 124.3, 126.0, 130.6, 142.2, 149.3,
151.7, 152.5, 152.7; HRESIMS m/z 351.1207 (calculated for
C19H20O5Na, 351.1209).
1,4,5,7-Tetramethoxy-phenanthrene (3b). Compound 2b
(2.81 g, 8.89 mmol) and P4-tBu (1 M, 11.50 mL, 11.56 mmol)
were placed under N2 in benzene and heated to 110uC for 19 h.
The solvent was evaporated and the crude product was
chromatographed on silica gel and eluted with EtOAc/n-hexane
(1:7) to yield 3b (3.59 g, 62.93%). Pale orange gum;
1H NMR
(CDCl3): d 3.95 (s, 3 H), 3.96 (s, 3 H), 3.98 (s, 3 H), 4.00 (s, 3 H),
6.72 (d, 1 H, J=2.4 Hz), 6.85 (d, 1 H, J=2.4 Hz), 6.90 (d, 1 H,
J=8.4 Hz), 7.01 (d, 1 H, J=8.4 Hz), 7.53 (d, 1 H, J=8.8 Hz),
8.07 (d, 1 H, J=8.8 Hz);
13C NMR (CDCl3): d 55.4, 55.8, 56.2,
56.3, 98.9, 99.8, 105.5, 108.3, 114.1, 120.7, 121.0, 124.3, 126.0,
135.5, 149.4, 151.5, 158.9, 159.1; ESIMS m/z 321 [M+Na]
+.
5,6,7-Trimethoxy-1,4-phenanthrenequinone (4a) and
5,6,7,59,69,79-hexamethoxy-[8,89]bi-1,4-
phenanthrenequinone (4c). Compound 3a (1.46 g,
4.45 mmol) and AgO (2.20 g, 17.76 mmol) were dissolved in
acetone. Oxidation was initiated by addition of 3.70 mL of 6 N
HNO3. The reaction was allowed to stir at 50uC until the grey
suspension disappeared (about 2–3 min). The reaction was
quenched immediately with H2O and CH2Cl2. The CH2Cl2
layer was dried over Na2SO4 and chromatographed on silica gel
and eluted with EtOAc/n-hexane (1:3) to yield 4a (385.46 mg,
29.76%) and 4c (393.85 mg, 14.93%).
Data for 4a: Red solid; mp 134uC;
1H NMR (CDCl3): d 3.96 (s,
3 H), 4.01 (s, 3 H), 4.04 (s, 3 H), 6.81 (d, 1 H, J=10.4 Hz), 6.96
(s, 1 H), 7.05 (d, 1 H, J=10.4 Hz), 7.86 (d, 1 H, J=8.4 Hz), 7.97
(d, 1 H, J=8.4 Hz);
13C NMR (CDCl3): d 56.1, 60.9, 61.2, 102.7,
120.2, 121.4, 130.8, 131.7, 133.3, 134.7, 135.2, 140.3, 143.8,
150.3, 155.7, 184.8, 186.7; ESIMS m/z 321 [M+Na]
+.
Data for 4c: Red solid; mp 100uC;
1H NMR (CDCl3): d 3.71 (s,
6 H), 3.99 (s, 6 H), 4.19 (s, 6 H), 6.83 (d, 2 H, J=10.0 Hz), 7.11
(d, 2 H, J=10.0 Hz), 7.30 (d, 2 H, J=8.4 Hz), 7.78 (d, 1 H,
J=8.4 Hz);
13C NMR (CDCl3): d 60.8, 61.1, 61.4, 119.6, 121.5,
122.1, 130.2, 131.5, 133.7, 134.0, 135.3, 140.4, 146.9, 151.1,
154.6, 184.7, 187.0; HRESIMS m/z 617.1421 (calcd for
C34H26O10Na, 617.1424).
5,7-Dimethoxy-1,4-phenanthrenequinone
(4b). Compound 3b (30.45 mg, 0.11 mmol), AgO (48.41 mg,
0.39 mmol), and 0.08 mL 6 N HNO3 were used with the method
Phenanthrenes as Cytotoxic Agents
PLoS ONE | www.plosone.org 11 May 2012 | Volume 7 | Issue 5 | e37897described for 4a and 4c. The crude product was chromatographed
on silica gel and eluted with EtOAc/n-hexane (1:7) to yield 4b
(8.14 mg, 28.80%). Red needles; mp 121uC;
1H NMR (CDCl3):
d 3.92 (s, 3 H), 3.94 (s, 3 H), 6.69 (d, 1 H, J=2.4 Hz), 6.76 (d, 1 H,
J=2.4 Hz), 6.78 (d, 1 H, J=10.4 Hz), 7.03 (d, 1 H, J=10.4 Hz),
7.85 (d, 1 H, J=8.8 Hz), 8.01 (d, 1 H, J=8.8 Hz);
13C NMR
(CDCl3):d55.6,55.9,99.1,101.9,116.9,122.6,130.4,131.7,134.1,
135.0, 139.4, 140.3, 158.3, 161.1, 184.8, 186.7; ESIMS m/z 291
[M+Na]
+.
3,5,6,7-Tetramethoxy-1,4-phenanthrenequinone (5a). p-
Toluenesulfonic acid (126.70 mg, 0.67 mmol) and ferric sulfate
(276.31 mg, 0.69 mmol) were added into the solution of 4a
(97.80 mg, 0.33 mmol) in 23 mL MeOH [14]. The mixture was
heated at 70uC for 2 h and poured into water as well as extracted
with CH2Cl2. The CH2Cl2 layer was dried over Na2SO4 and
chromatographed on silica gel and eluted with CH2Cl2 to yield 5a
(93.09 mg, 86.48%). Yellow solid; mp 174uC;
1H NMR (CDCl3):
d 3.93 (s, 3 H), 3.94 (s, 3 H), 4.01 (s, 3 H), 4.08 (s, 3 H), 6.02 (s,
1 H), 6.96 (s, 1 H), 7.87 (d, 1 H, J=8.4 Hz), 8.00 (d, 1 H,
J=8.4 Hz);
13C NMR (CDCl3): d 56.0, 56.5, 60.8, 61.1, 102.6,
106.3, 120.3, 121.4, 131.2, 132.1, 132.2, 134.4, 143.8, 150.1,
155.4, 163.0, 182.0, 184.7; ESIMS m/z 351 [M+Na]
+.
3,5,7-Trimethoxy-1,4-phenanthrenequinone (5b) and
3,3,5,7-tetramethoxy-2,3-dihydro-1,4-
phenanthrenequinone (5c). Compound 4b (202.92 mg,
0.76 mmol), p-toluenesulfonic acid (295 mg, 1.55 mmol), ferric
sulfate (618 mg, 1.55 mmol) and 40 mL MeOH were used with
the method described for 5a. The crude product was chromato-
graphed on silica gel and eluted with CH2Cl2 to yield 5b
(183.71 mg, 81.42%) and 5c (11.51 mg, 4.60%).
Data for 5b: Orange solid; mp 179uC;
1H NMR (CDCl3): d 3.92
(s, 3 H), 3.93 (s, 6 H), 5.99 (s, 1 H), 6.69 (d, 1 H, J=2.4 Hz), 6.76
(d, 1 H, J=2.4 Hz), 7.87 (d, 1 H, J=8.4 Hz), 8.04 (d, 1 H,
J=8.4 Hz);
13C NMR (CDCl3): d 55.6, 55.9, 56.5, 99.1, 101.9,
106.2, 116.9, 122.6, 130.8, 132.3, 132.7, 139.0, 158.1, 160.8,
162.9, 181.8, 184.6; ESIMS m/z 321 [M+Na]
+.
Data for 5c: Pale yellowish solid; mp 149uC;
1H NMR (CDCl3):
d 3.29 (s, 2 H), 3.44 (s, 6 H), 3.92 (s, 3 H), 3.95 (s, 3 H), 6.67 (d,
1H , J=2.4 Hz), 6.81 (d, 1 H, J=2.4 Hz), 7.84 (d, 1 H,
J=8.8 Hz), 7.99 (d, 1 H, J=8.8 Hz);
13C NMR (CDCl3):
d 48.8, 50.3, 50.3, 55.6, 55.7, 99.5, 101.2, 101.5, 116.7, 123.2,
131.0, 132.3, 137.5, 139.6, 157.6, 161.4, 191.8, 196.9; HRESIMS
m/z 353.0999 (calculated for C18H18O6Na, 353.1001).
3,5,6,7,39,59,6,79-Octamethoxy-[8,89]bi-1,4,19,49-
phenanthrenequinone (5d), 3,5,6,7,39,39,59,6,79-
nonamethoxy-2939-dihydro-[8,89]bi-1,4,19,49-
phenanthrenequinone (5e), and 3,5,6,7,19,59,69,79-
octamethoxy-[8,89]bi-1,4,59,69-phenanthrenequinone
(5f). Compound 4c (196.33 mg, 0.33 mmol), p-toluenesulfonic
acid (277.8 mg, 1.46 mmol), ferric sulfate (531.90 mg, 1.33 mmol)
and 20 mL MeOH were used with the method described for 5a.
The crude product was chromatographed on silica gel and eluted
with EtOAc/n-hexane (1:2) to yield 5d (107.54 mg, 49.70%), 5e
(33.57 mg, 14.80%) and 5f (20.32 mg, 9.40%).
Data for 5d: Orange solid; mp 268uC;
1H NMR (CDCl3): d 3.71
(s, 6 H), 3.97 (s, 6 H), 3.98 (s, 6 H), 4.22 (s, 6 H), 6.04 (s, 2 H),
7.31 (d, 1 H, J=8.8 Hz), 7.81 (d, 1 H, J=8.8 Hz);
13C NMR
(CDCl3): d 56.7, 60.7, 61.1, 61.4, 106.4, 119.7, 121.5, 122.2,
130.8, 132.0, 132.4, 133.8, 146.9, 150.8, 154.3, 163.0, 182.3,
184.4; HRESIMS m/z 677.1639 (calcd for C36H30O12Na,
677.1635).
Data for 5e: Orange solid; mp 124uC;
1H NMR (CDCl3): d 3.32
(s, 2 H), 3.50 (s, 3 H), 3.51 (s, 3 H), 3.69 (s, 3 H), 3.71 (s, 3 H),
3.96 (s, 3 H), 3.97 (s, 6 H), 4.20 (s, 3 H), 4.22 (s, 3 H), 6.04 (s,
1 H), 7.24 (d, 1 H, J=8.8 Hz), 7.30 (d, 1 H, J=8.8 Hz), 7.72 (d,
1H ,J=8.8 Hz), 7.81 (d, 1 H, J=8.8 Hz);
13C NMR (CDCl3):
d 49.0, 50.4, 50.5, 56.7, 60.5, 60.7, 60.8, 61.1, 61.2, 61.3, 101.7,
106.4, 119.6, 120.0, 121.5, 122.0, 122.2, 122.3, 129.3, 130.8,
132.0, 132.4, 133.3, 133.7, 134.1, 137.5, 146.2, 146.9, 150.3,
150.8, 154.3, 154.9, 163.0, 182.3, 184.4, 191.8, 197.7; HRESIMS
m/z 709.1901 (calculated for C37H34O13Na, 709.1897).
Data for 5f: Orange solid; mp 146uC;
1H NMR (CDCl3): d 3.69
(s, 3 H), 3.70 (s, 3 H), 3.96 (s, 3 H), 3.97 (s, 3 H), 3.98 (s, 3 H),
3.99 (s, 3 H), 4.19 (s, 3 H), 4.22 (s, 3 H), 5.87 (s, 1 H), 6.04 (s,
1 H), 7.27 (d, 1 H, J=8.8 Hz), 7.32 (d, 1 H, J=8.8 Hz), 7.61 (d,
1H ,J=8.8 Hz), 7.82 (d, 1 H, J=8.8 Hz);
13C NMR (CDCl3):
d 56.7, 57.1, 60.7, 61.1, 61.2, 61.3, 101.3, 106.5, 119.5, 119.7,
120.4, 121.5, 122.1, 124.2, 130.9, 131.1, 131.8, 132.0, 132.4,
132.5, 132.7, 133.8, 146.9, 147.0, 150.5, 150.8, 154.0, 154.3,
163.0, 169.2, 182.3, 184.4, 185.0, 186.7; HRESIMS m/z
677.1639 (calculated for C36H30O12Na, 677.1635).
5-Hydroxy-3,6,7-trimethoxy-1,4-phenanthrenequinone;
calanquinone A (6a). Compound 5a (115.02 mg, 0.35 mmol)
was dissolved in 5 mL CH2Cl2 and iodotrimethylsilane
(112.23 mg, 0.56 mmol) was added to the solution in portions.
The mixture was stirred at 60uC overnight (TLC monitoring) and
then MeOH was added to quench the reaction. The solvent was
evaporated and the residue extracted with Et2O/H2O. The Et2O
layer was dried over Na2SO4. The mixture was chromatographed
on silica gel and eluted with EtOAc/n-hexane (1:2) to yield 6a
(15.72 mg, 14.28%). Black solid; mp 187uC;
1H NMR (CDCl3):
d 3.96 (s, 3 H), 4.01 (s, 3 H), 4.02 (s, 3 H), 6.14 (s, 1 H), 6.85 (s,
1 H), 8.03 (d, 1 H, J=8.4 Hz), 8.08 (d, 1 H, J=8.4 Hz), 10.73 (s,
OH);
13C NMR (CDCl3): d 55.9, 56.9, 60.8, 101.2, 107.2, 118.5,
121.7, 128.1, 132.8, 134.8, 136.9, 140.1, 148.1, 155.0, 161.5,
184.4, 186.0; HRESIMS m/z 313.0648 (calculated for C17H14O6
-H, 313.0712).
5-Hydroxy-3,7-dimethoxy-1,4-phenanthrenequinone;
denbinobin (6b). Compound 5b (67.56 mg, 0.23 mmol) and
iodotrimethylsilane were used with the method described for 6a.
The crude product was chromatographed on silica gel and eluted
with CH2Cl2 to yield 6b (6.0 mg, 10%). Black solid; mp 215uC
[21];
1H NMR (CDCl3): d 3.93 (s, 3 H), 3.96 (s, 3 H), 6.15 (s,
1 H), 6.82 (d, 1 H, J=2.8 Hz), 6.93 (d, 1 H, J=2.8 Hz), 8.06 (d,
1H ,J=8.8 Hz), 8.12 (d, 1 H, J=8.8 Hz), 11.00 (s, OH);
13C
NMR (CDCl3): d 55.5, 56.9, 101.8, 107.3, 108.7, 117.2, 122.6,
128.6, 132.4, 137.4, 139.9, 156.4, 160.8, 161.2, 184.4, 186.5;
HRESIMS m/z 307.0584 (calculated for C16H12O5 Na,
307.0582).
5-Acetoxy-3,6,7-trimethoxy-1,4-phenanthrenequinone
(7a) and 5-acetoxy-3,7-dimethoxy-1,4-phenanthrenequinone
(7b). Compounds 6a (3.29 mg, 0.01 mmol) and 6b (2.03 mg,
0.007 mmol) were each dissolved in pyridine and excess Ac2O was
added to the two solutions. The mixture was stirred at RT
overnight and the pyridine was evaporated. The crude material
was chromatographed on silica gel and eluted with EtOAc/n-
hexane (1:2) to afford 7a (4.65 mg, 124.66%) and 7b (2.80 mg,
120.10%), respectively.
Data for 7a: Yellow green solid; mp 196uC;
1H NMR (CDCl3):
d 2.36 (s, 3 H), 3.93 (s, 3 H), 3.99 (s, 3 H), 4.03 (s, 3 H), 6.05 (s,
1 H), 7.15 (s, 1 H), 7.97 (d, 1 H, J=8.8 Hz), 8.07 (d, 1 H,
J=8.8 Hz);
13C NMR (CDCl3): d 20.8, 56.0, 56.6, 60.8, 106.0,
106.4, 119.4, 121.6, 130.2, 132.1, 133.1, 134.1, 139.7, 144.2,
154.9, 162.7, 168.4, 181.8, 184.4; HRESIMS m/z 379.0791
(calculated for C19H16O7Na, 379.0794).
Data for 7b: Yellow solid; mp 201uC;
1H NMR (CDCl3): d 2.32
(s, 3 H), 3.93 (s, 3 H), 3.96 (s, 3 H), 6.06 (s, 1 H), 7.10 (d, 1 H,
J=2.4 Hz), 7.15 (d, 1 H, J=2.4 Hz), 8.00 (d, 1 H, J=8.4 Hz),
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13C NMR (CDCl3): d 21.1, 55.8, 56.6,
105.3, 106.5, 116.3, 118.2, 122.6, 131.0, 131.6, 133.3, 138.8,
148.0, 159.6, 162.5, 168.8, 181.9, 184.4; HRESIMS m/z
349.0686 (calculated for C18H14O6Na, 349.0688).
5,6-Dihydroxy-1,4,7-trimethoxy-phenanthrene (8a) and 5-
hydroxy-1,4,6,7-tetramethoxy-phenanthrene
(9a). Compound 3a (109.39 mg, 0.33 mmol) was dissolved in
benzene, and AlCl3 (987 mg, 7.40 mmol) was added to the
solution in portions. The mixture was stirred at 70uC overnight
(TLC monitoring) and poured into 50 mL of ice-water along with
5 mL concentrated hydrochloric acid [14]. The suspension was
extracted with CH2Cl2 and dried over Na2SO4. The crude
material was chromatographed on silica gel and eluted with
EtOAc/n-hexane (1:2) to yield 8a (44.49 mg, 44.47%) and 9a
(9.33 mg, 8.91%).
Data for 8a: Pale brownish solid; mp 116uC;
1H NMR (CDCl3):
d 3.94 (s, 3 H), 4.01 (s, 3 H), 4.06 (s, 3 H), 6.33 (s, OH), 6.95 (d,
1H ,J=8.4 Hz), 6.98 (s, 1 H), 7.20 (d, 1 H, J=8.4 Hz), 7.60 (d,
1H ,J=9.6 Hz), 8.03 (d, 1 H, J=9.6 Hz), 10.77 (s, OH);
13C
NMR (CDCl3): d 56.0, 56.1, 60.7, 101.6, 105.3, 113.2, 113.5,
117.8, 121.0, 124.7, 127.6, 127.7, 135.3, 140.6, 147.7, 147.8,
152.0; HRESIMS m/z 323.0894 (calculated for C17H17O5Na,
323.0895).
Data for 9a: Pale yellowish solid; mp 124uC;
1H NMR (CDCl3):
d 3.94 (s, 3 H), 3.99 (s, 3 H), 4.01 (s, 3 H), 4.03 (s, 3 H), 6.93 (s,
1 H), 6.96 (d, 1 H, J=8.4 Hz), 7.21 (d, 1 H, J=8.4 Hz), 7.59 (d,
1H ,J=9 Hz), 8.10 (d, 1 H, J=9 Hz), 10.52 (s, OH);
13C NMR
(CDCl3): d 55.8, 56.2, 60.3, 60.8, 101.1, 105.4, 113.7, 114.2,
119.4, 121.6, 124.5, 127.5, 131.1, 137.9, 147.7, 149.0, 151.9,
153.2; HRESIMS m/z 337.1054 (calculated for C18H18O5Na,
337.1052).
4-Hydroxy-1,5,7-trimethoxy-phenanthrene (8b) and 5-
hydroxy-1,4,7-trimethoxy-phenanthrene (9b). Compound
3b (91.65 mg, 0.32 mmol), AlCl3 (509.60 mg, 3.82 mmol), and
benzene were used with the method described for 8a and 9a. The
crude was chromatographed on silica gel and eluted with EtOAc/
n-hexane (1:7) to yield 8b (20.00 mg, 22.77%) and 9b (22.00 mg,
24.9%).
Data for 8b: Pale brownish solid; mp 71uC;
1H NMR (CDCl3):
d 3.97 (s, 3 H), 3.99 (s, 3 H), 4.06 (s, 3 H), 6.85 (d, 1 H,
J=2.4 Hz), 7.00 (d, 1 H, J=8.8 Hz), 7.01 (d, 1 H, J=2.4 Hz),
7.16 (d, 1 H, J=8.8 Hz), 7.55 (d, 1 H, J=8.8 Hz), 8.21 (d, 1 H,
J=8.8 Hz), 9.12 (s, OH);
13C NMR (CDCl3): d 55.6, 56.4, 58.2,
101.6, 103.4, 107.6, 114.3, 115.6, 119.8, 122.3, 124.1, 125.7,
136.2, 147.5, 149.1, 155.5, 158.3; HRESIMS m/z 307.0948
(calculated for C17H16O4Na, 307.0946).
Data for 9b: Pale brownish solid; mp 70uC;
1H NMR (CDCl3):
d 3.92 (s, 3 H), 3.94 (s, 3 H), 4.00 (s, 3 H), 6.89 (d, 1 H,
J=2.8 Hz), 6.92 (d, 1 H, J=2.8 Hz), 6.94 (d, 1 H, J=8.8 Hz),
7.20 (d, 1 H, J=8.8 Hz), 7.61 (d, 1 H, J=8.8 Hz), 8.13 (d, 1 H,
J=8.8Hz), 10.38 (s, OH);
13C NMR (CDCl3): d 55.3, 56.1, 60.4,
102.5, 104.7, 105.4, 113.1, 114.2, 120.4, 121.8, 124.3, 127.8,
136.4, 147.6, 151.9, 156.4, 159.3; HRESIMS m/z 307.0947
(calculated for C17H16O4Na, 307.0946).
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